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Abstract: Introduction: Cerebellar degeneration has been associated in patients with epilepsy, though
the exact pathogenic mechanisms are not understood. The aim of this systematic review was to iden-
tify the prevalence of cerebellar degeneration in patients with epilepsy and identify any pathogenic
mechanisms. Methodology: A systematic computer-based literature search was conducted using
the PubMed database. Data extracted included prevalence, clinical, neuroradiological, and neu-
ropathological characteristics of patients with epilepsy and cerebellar degeneration. Results: We
identified three consistent predictors of cerebellar degeneration in the context of epilepsy in our
review: temporal lobe epilepsy, poor seizure control, and phenytoin as the treatment modality. Whole
brain and hippocampal atrophy were also identified in patients with epilepsy. Conclusions: Cerebel-
lar degeneration is prevalent in patients with epilepsy. Further prospective studies are required to
confirm if the predictors identified in this review are indeed linked to cerebellar degeneration and to
establish the pathogenic mechanisms that result in cerebellar insult.
Keywords: epilepsy; cerebellar degeneration; ataxia
1. Introduction
Epilepsy affects approximately 50 million people worldwide [1] and an estimated
362,000 to 415,000 people in England [2]. Epilepsy is characterised by recurrent and unpro-
voked seizures [3]. Based on the International League Against Epilepsy (ILAE) Guidelines,
epilepsy can be classified by seizure type, epilepsy type, and epilepsy syndrome. Causes of
epilepsy include structural, genetic, infectious, metabolic, immune, and unknown factors [4].
Much of what is known about the cerebellum stems from examining the consequences
of damage to it [5]. The classical symptoms of cerebellar dysfunction include a broad array
of clinical signs, with the most commonly noted being ataxia (a combination of slurred
speech, limb incoordination, and gait instability) [6].
The past three decades have witnessed a shift in our understanding of the cerebellum,
its function and significance in various neurological conditions [7]. This new understand-
ing, challenges traditional views, suggesting that the cerebellum is associated with the
modulation of a variety of cognitive functions including perception, language, memory,
and emotion [8–11].
Cerebellar degeneration refers to the chronic and irreversible loss of neuronal struc-
ture and function within the cerebellum [12]; the Purkinje cells are most susceptible. The
causes of cerebellar degeneration can be broadly divided into two categories; acquired
and genetic [13]. Acquired cerebellar degeneration has been attributed to endogenous or
exogenous non-genetic causes [14], such as alcohol abuse and vitamin deficiencies [15],
infections of the central nervous system (CNS) [16], autoimmune disorders [17], and pri-
mary or metastatic tumours [17], among others. Neuroimaging studies including magnetic
resonance (MR) and nuclear medicine techniques such as single-photon emission computed
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tomography (SPECT) and positron emission tomography (PET) provide structural and
functional assessments of cerebellar atrophy [18].
Cerebellar degeneration has been associated with epilepsy [19]. Marcian et al., (2016) [19]
postulated a triad of questions; is cerebellar dysfunction a coincidence, consequence, or
cause of epilepsy. The authors suggested that cerebellar degeneration can be attributed
to cellular damage from seizure activity, the effects of anti-epileptic drugs (AEDs), anoxic-
ischaemic injury from seizures, or cerebral hemiatrophy of the cerebellum [20–22]. Some
patients with epilepsy display variable severity of ataxia as a result of structural cerebellar
damage. Sometimes this is merely part of a syndrome where both epilepsy and cerebellar
degeneration are features (e.g., mitochondrial diseases), but in many cases, ataxia may be
a direct result of seizure mediated cell loss or an adverse effect of certain anti-epileptic
medication. Cerebellar damage is also said to result in disinhibition of cerebral epileptic
activity. Animal studies have evidenced that cerebellar stimulation induces inhibition
of paroxysmal epileptic waves in the cerebrum. Complete ablation of the cerebellum
exhibited continuous hypersynchronous activity, in Sprague Dawley rats [23]. Studies
linking radiological evidence of cerebellar dysfunction with clinical cerebellar ataxia in
patients with epilepsy is also limited. However, the question still remains as to whether
atrophy of the cerebellum, causing it to lose its inhibitory effect on cerebral epileptic activity,
is the cause or effect of worsening disease progression.
The aim of this study was to systematically review the current literature in order
to establish the prevalence of cerebellar degeneration in patients with epilepsy by iden-




This review is registered on the database of dissertation projects for the MSc in
Clinical Neurology at the University of Sheffield, UK. This review is not registered on a
public database.
2.2. Search Strategy
A systematic PubMed search was performed between 27 April 2019 and 11 July 2019.
Two Medical Subject Headings (MeSH) were used in the search. Term A was “cerebellar
degeneration OR cerebellar atrophy OR cerebellar ataxia OR cerebellar dysfunction”. Term
B was “epilepsy OR epileptic OR epilepsia”. No date restrictions were applied in the
search strategy.
2.3. Inclusion Criteria
In order to be included for the review, studies were required to meet the following
criteria:
1. All recruited in the studies were human subjects
2. All patients were diagnosed with epilepsy
3. All studies discussed cerebellar degeneration in relation to epilepsy and/or anti-
epileptic drugs
4. All studies investigated clinical and/or neuroimaging and/or pathological findings
of cerebellar degeneration in patients with epilepsy
5. The full publication text was written in English
2.4. Exclusion Criteria
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4. Studies reporting patients with encephalopathy or status epilepticus or post stroke
epilepsy
5. Studies detailing cerebellar degeneration in epilepsy caused by another disorder, e.g.,
alcohol related, autoimmune, mitochondrial
6. Studies where the patient group had been used in multiple studies
All studies were screened and assessed for eligibility by two authors (M.I. and P.D.S.)
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Figure 1. PRISMA chart illustrating the article inclusion and exclusion process. (MeSH: medical subject headings, x: number
of studies).
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2.5. Data Extraction Process
Data was extracted from included studies by a structured coding scheme using Google
Sheets in the following format:
1. Study details (author, year of publication, study design, location of study); population
demographics (size, age, and gender)
2. Epilepsy characteristics (classification of epilepsy; seizure or epilepsy type, duration
of epilepsy, seizure control); anti-epileptic drug (AED) therapy (monotherapy or
polytherapy, type of AED at study onset, and duration of treatment).
3. Clinical characteristics of cerebellar degeneration included gait and/or limb ataxia,
tremor, nystagmus, and clinical signs of peripheral neuropathy
4. Neuroimaging characteristics included whether cerebellar atrophy was “present” or
“absent”; if present whether this was single or bilateral cerebellar hemispheric atrophy,
vermian atrophy, or whole cerebellar atrophy); and any focal brain structural changes
5. Neuropathological characteristics on post-mortem included microscopic and macro-
scopic descriptions of the cerebellum, and when available cause of death.
For the purpose of this review, we referred to the latest 2017 International League
Against Epilepsy (ILAE) terminology and definitions of epilepsy [4].
2.6. Synthesis of Results
The data extracted was analysed in a chronicle and qualitative manner rather than
by quantitative or meta-analysis. This review was performed to comply with the stan-
dardised “Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)
guidelines”.
2.7. Assessment of Bias
A risk of bias tool was not necessary in this review as none of the included publications
were randomised control trials or interventional studies.
2.8. Ethical Guidelines
This is based on previous published research and is in accordance with the University
of Sheffield’s ethical guidelines.
3. Results
3.1. Selected Studies
The final PubMed search identified 1787 articles. After limitations were applied (Hu-
mans and English Language) 553 articles were excluded before screening. Article screening
was performed on two levels: level I, title screening and level II, abstract screening. Level I
assessed studies based on title alone. Studies were rejected if they had a definite observable
exclusion criterion. In instances where there was no obvious exclusion criterion, abstracts
were reviewed. Based on level I screening, 1125 articles were excluded and by level II
screening, a further 49 studies were excluded.
A total of 10 articles were excluded in the full text eligibility assessment. Of these,
four were studies whereby the patient population had been used in multiple studies of
cerebellar degeneration in epilepsy [24–27]. In such a case, the full text of each study was
reviewed and compared against the other. The study judged to have the most data rich and
relevant information was subsequently used in the analysis. In relation to the longitudinal
studies by Liu et al., [26] and [27], the most recent study was used [28]. Four articles were
excluded on the basis that the patient group were not explicitly diagnosed with epilepsy,
and two because the full text was written in a language other than English. Finally, a total
of 50 studies met the inclusion criteria and constitute our dataset [20–22,28–74]. Table 1
and Supplementary Table S2 summarises the study characteristics included.
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3.2. Epilepsy Characteristics
Thirty-six studies (n = 2065) [20,21,28,29,34–37,39–41,44,46–49,51,52,54–70,74], reported
a pooled prevalence of epilepsy classification of either focal (90.3%), generalized (6.5%), or
unclassified (3.2%) epilepsy. Patients with TLE represented the vast majority of classifica-
tions (n = 1503). However, this may be because 21 of these studies exclusively investigated
patients with TLE (n = 1372) [21,39,47,49,51,54–67,69,70].
Table 1. Summary of study characteristics included.
Total Number of Studies Included in this Review 50














Number of patients with epilepsy studied
Total number of patients with epilepsy 2826
Mean number of patients per study (SD) 56.5 (54.6)
Range 3–248
Median 41
SD = standard deviation.
3.3. Antiepileptic Medication History
For many years phenytoin was considered one of the first-line AEDs for several epilepsy
syndromes [75]. Hagemann et al., (2002) [50] speculates that cerebellar damage is a direct
consequence of long-term seizures and or AEDs. It can be seen from the data in Table 2 that
the AEDs most widely used were phenytoin (44%), phenobarbital (15.5%), carbamazepine
(14.3%), and sodium valproate (8.2%). Twenty-three studies commented on whether the phar-
macological treatment was monotherapy or polytherapy, with (n = 430) and (n = 804) pa-
tients, respectively [20,29–32,34,36–39,41,44–47,55,61,63,66,69,71–73]. There were a lack of stud-
ies reporting duration of AED treatment, a factor that could prove essential in determining
the contributors to cerebellar degeneration. However, given the well-recognised adverse ef-
fects of phenytoin [76], there were only nine studies [20,22,32,33,35,37,41,42,53] that detailed
the duration of phenytoin treatment, with a pooled mean duration of 9.3 years, ranging
from 0.8 to 67 years. Twenty-nine studies reported on the seizure control of patients with
epilepsy [20,21,30,34,35,37,40,42,43,45–49,51,52,54,58–62,65,66,68–70,72,74] (n = 1303). Of these,
eight studies reported 11.2% patients pharmaco-responsive (n = 147) and one study detailed
2.1% patients as relapsing-remitting (n = 28) to treatment. However, 25 studies observed 86.5%
(n = 1128) patients as pharmaco-resistant to treatment.
3.4. Prevalence of Cerebellar Degeneration
3.4.1. Clinical Characteristics
Fourteen studies reported results from clinical examinations of cerebellar dysfunction,
with a total of 788 patients [21,29–41]. However, quantitative data could only be extrapo-
lated from 13 studies, as some studies merely stated an observation of a clinical cerebellar
sign (ataxia, gait ataxia, limb ataxia, tremor, or nystagmus), but did not provide a figure.
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Additionally, three other studies [31,33,36] reported the presence of ataxia but provided
figures for other clinical signs.
The pooled prevalence of the clinical signs of cerebellar dysfunction, from the 13
studies, was 264 (40%) of 657 patients. Nine studies provided information on “ataxia” and
provided a pooled prevalence of 156 (24%) patients. Majority of these studies focused
on investigating cerebellar atrophy in patients with epilepsy. From these, gait ataxia
represented 10%, limb ataxia represented 4%, and the combination of gait and limb ataxia,
reported as a clinical sign together, was determined in 14 patients gave a figure of 2%.
Table 2. Number of patients on monotherapy and polytherapy anti-epileptic drug (AED) medications
at study onset.
Type of Treatment (%)
Monotherapy 430 (34.8)
Polytherapy 804 (65.2)
AED Type Number of Patients (%)
Phenytoin 914 (44)
Phenobarbital * 324 (15.5)
Carbamazepine 299 (14.3)


















* Includes barbiturate variants.
Nystagmus was the most frequently observed clinical feature, 10.3% (n = 81) in 10
studies that made reference to it [29,31,33,35–41], whilst tremor represented only 3.4%
of the total clinical examination population. However, Specht et al., (1994, 1997) [36,39]
contributed the majority of observations on the presence of nystagmus, with 23 and 22
patients, respectively. In both studies, this was related to Carbamazepine intoxication.
Reports on peripheral neuropathy were limited. Two of three studies reported no
peripheral neuropathy [33,41] and the other reported peripheral neuropathy in 15 pa-
tients [31].
Clinical vs. Imaging Characteristics
Of the (n = 264) patients documented as having clinical signs of cerebellar dysfunction,
86.7% had cerebellar atrophy via neuroimaging. Volumetric MRI represented (n = 67)
patients; MR Spectroscopy (n = 8); CT (n = 28); SPECT (n = 4); and PEG (n = 122). Moreover,
129 patients displayed vermian atrophy, while 37 also evidenced whole brain atrophy.
Clinical vs. Epilepsy and AED Characteristics
Of the total of 788 patients with epilepsy from 13 studies, only nine studies reported
the classification of epilepsy, totalling 374 patients [21,29,34–37,39–41]. In this patient group,
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temporal lobe epilepsy (TLE) represented 38.5%, focal unspecified epilepsy represented
34.5% and focal to bilateral, 2.7%. Generalised epilepsy represented 14.7% and unknown
epilepsy 17.6% of patients. These patients were also more likely to use polytherapy as a
treatment method, 69.5% (n = 453) as opposed to monotherapy, 30.5%, (n = 199). The AEDs
most frequently used in this group were phenytoin 41.5% (n = 555), phenobarbital 16%
(n = 214), and carbamazepine 10% (n = 133), of a total 1337 AEDs administered.
3.4.2. Neuroimaging Characteristics
Radiological Techniques and Sequences
Forty-three studies, totalling (n = 2451) patients, detailed neuroimaging of the cere-
bellum [20–22,28,29,32–37,39–70]. The preferred method of imaging was Volumetric MRI,
with 52% studies employing this method. A further 16% used volume-based morphome-
try (VBM); computed tomography (CT) was used in 10%; SPECT in 6%; diffusion tensor
imaging (DTI); and PET represented 4% of studies each; MR Spectroscopy and deformation-
based morphometry (DBM) accounted for 2% of studies each. However, due to the varia-
tions in result reporting across studies, only 19 reported quantitative data.
Imaging Characteristics—Brain Atrophy
Twenty-one studies reported whole brain atrophy, in predominantly white matter
regions [22,28,29,32,33,35,36,44,45,47–50,54,57,60–62,65,66,68]. Data from six studies [22,29,32,33,36,47],
totalling 349 patients provided a prevalence of 21.2% for whole brain atrophy.
Imaging Characteristics—Hippocampal Atrophy
Hippocampal atrophy was identified in fifteen studies (n = 1026)
[22,28,40,51,54,56,58–62,65,66,69,70]. Of the fifteen studies that reported hippocampal at-
rophy, all but three [22,28,40], specifically recruited patients with TLE. Quantitative data
drawn from eight studies (n = 597) [22,28,40,51,58,61,69,70] showed that 77.5% were pa-
tients with TLE, and of these 45% (n = 269) were observed to have hippocampal atrophy.
In line with previous research [77], we identified widespread grey matter volume
(GMV) reductions in the extra-hippocampal regions, including the thalamus and limbic
structures, as well as, cerebellar regions [62]. This GMV loss was most pronounced in
regions ipsilateral to the epileptogenic focus. That is, reductions in the left cerebellum
were observed in left-TLE patients, while right-TLE patients showed bilateral cerebellar
reductions [51,56]. However, other studies identified bilateral GMV reductions in the
cerebellum of patients with left-TLE and hippocampal sclerosis (HS) [58,65]. Similarly,
Oyegbile et al., (2011) [63] found no significant difference of total cerebellar tissue volume,
including both GMV and white matter volume (WMV) between left- and right-TLE patients.
Brain Atrophy vs. Type of Epilepsy vs. AED
Focal epilepsy comprised 85.5% amongst 1169 patients, while generalised epilepsy
represented 10.1% (n = 119), and unclassified epilepsy 4.3% (n = 51). Amongst the 999
patients with focal epilepsy, 74.6% had TLE. Based on this, it appears there is a moderately
greater tendency for whole brain atrophy to be associated with focal epilepsy. The majority
of these patients had poor seizure control 85.1% (n = 606). Polytherapy was the treatment
modality for 383 patients, compared to 220 using monotherapy. The most prevalent
AEDs taken in this group were phenytoin 34% (n = 274), carbamazepine 22.5% (n = 181),
phenobarbital 11.2% (n = 90), and barbiturate variants 6.6% (n = 53).
Imaging Characteristics—Cerebellar Atrophy
The pooled prevalence of cerebellar atrophy based on neuroimaging was 37.5%
(n = 337), compared to 62.4% (n = 561) patients that detected no neuroimaging signs of
cerebellar atrophy. The majority of cases report significant cerebellar loss of volume. Some
studies suggest a linear relationship between the duration of epilepsy and cerebellar volume
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loss [21,28,32,49,51,52,54,57,59,63,66]. That is, cerebellar volume decreased as the duration
of epilepsy increased, whereas six studies did not find an association [35,37,44,48,50,68].
The loss of cerebellar volume was primarily limited to grey matter. Some studies identi-
fied that abnormalities varied across cerebellar hemispheres. Five studies showed bilateral
grey matter volume reductions regardless of classification of epilepsy [61,63,65,69,70],
Keller et al., (2002 and 2004) [25,51,56] reported that patients with right-TLE focus, pre-
sented with bilateral grey matter atrophy, compared with left-TLE patients, who showed
ipsilateral reductions in grey matter, using VBM techniques. Using the same modality,
Riederer et al., (2008) [60] identified bilateral grey matter reductions in patients with left-
TLE. Conversely, Alvim et al., (2016) [69] studied 35 patients whose seizure freedom ranged
from 2 to 11 years and observed diffuse grey matter volume reductions in TLE patients,
despite prolonged seizure freedom.
Of the forty-three neuroimaging studies identified in our systematic review, five of
these used two different neuroimaging techniques each [22,41,48,62,64]. It was difficult to
ascertain whether the patients observed one neuroimaging technique or if they were indeed
the same patients who underwent both imaging scans and had their results repeated.
Eight studies identified vermian atrophy in their investigations [21,32,35,39,41,42,50,62].
Data from six studies, with a total of (n = 353) patients provided a pooled prevalence of
42% (n = 148) vermian atrophy. Conversely, Oyegbile et al., (2011) [63] and Marcian et al.,
(2018) [70] identified an inverse relationship between the cerebellar hemispheres and
vermis. That is, the greater the reduction in grey matter volume within the cerebellar
hemispheres, the larger the grey matter volume in the anterior lobe of the vermis. This
effect was more pronounced in TLE patients who also had hippocampal sclerosis.
3.4.3. Neuropathological Characteristics
Six studies reported cerebellar pathology [22,30,71–74], totalling 125 patients. Four
studies investigated autopsy pathology [22,72–74], whilst one exclusively studied brain
biopsy [30] and another explored both autopsy and biopsy pathology [74]. Seizure control
was only reported in three studies [30,72,74] whereby 62.4% (n = 78) patients showed
resistance to pharmacological treatment. A total of 72 patients were on polytherapy com-
pared to monotherapy treatment, 39 patients. The most common drug implicated for
these pathology patients was phenytoin 30.3% (n = 41), followed by phenobarbital 23.7%
(n = 32) and carbamazepine 16.3% (n = 22) (Table 3). Data for epilepsy classification was
not available in these studies.
Table 3. Table demonstrating the number of patients taking each anti-epileptic drug (AED) for seizure
control based on neuropathological studies.












(Note: retrospective data from medical reports).
Cerebellar degeneration was reported in five pathology studies [22,30,71,72,74] and
detailed a pooled prevalence cerebellar degeneration of 60.4% of (n = 101) autopsied and
biopsied patients in their investigations. Cerebellar degeneration in this group mani-
fested as significant Purkinje cell loss and a severely atrophied cerebellum. Crooks et al.,
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(2000) [22] found that Purkinje cell loss was higher with increased duration of seizures,
although it was difficult to differentiate between seizure duration and age effects.
A high proportion of sudden unexpected death in epilepsy (SUDEP) was reported in
these studies. Specifically, 87 (69.6%) deaths were caused by SUDEP in this group [22,72–74],
while 25 deaths were associated with chronic diseases such as cardiorespiratory insuffi-
ciency and coronary diseases [22,73]. One patient committed suicide [74].
The high proportion of SUDEP in these studies can be explained by the fact that
Shield et al., (2002) [72] based their neuropathological investigations exclusively on SUDEP
brains comparing them to healthy controls. They found a significantly large proportion
of SUDEP cases to have neuronal clusters, while the controls displayed both a higher
percentage of oligodendroglial clusters and heterotopic neurons in white matter. Both
cerebellar and cerebral atrophy was present in these cases. It would be of interest to
distinguish possible differences in cerebellar atrophy between SUDEP and patients with
epilepsy that died of other causes.
4. Discussion
To our knowledge, this is the first systematic review investigating cerebellar degener-
ation in patients with epilepsy. We aimed to identify patterns of cerebellar degeneration
in relation to clinical, neuroimaging and pathological characteristics. We also set out to
identify any links between cerebellar degeneration with seizure type and AEDs.
Through qualitative synthesis of our dataset, we identified several factors that are as-
sociated with cerebellar degeneration across clinical, neuroimaging and pathology studies.
Supplementary Table S1 provides a summary of the key findings. The three main factors
are (1) patients who have temporal lobe epilepsy, (2) patients with poor seizure control,
and (3) patients treated with phenytoin.
4.1. TLE and Cerebellar Degeneration
Although cerebellar degeneration was evident in patients with epilepsy regardless of
epilepsy classification, it was most prevalent in patients with TLE. Temporal lobe epilepsy
is the most common pharmaco-resistant epilepsy in adults [78] and frequently requires
resective surgery of the affected temporal lobe [79]. It is characterised by seizures that arise
anywhere within the temporal lobe. In TLE, the seizure originates in the limbic structures
within the temporal lobe, more specifically, the hippocampus [77,80]. Hippocampal sclero-
sis is a hallmark feature of drug-resistant TLE and characterised by neuronal death, gliosis,
and atrophy [81].
Additionally, Bonilha et al., (2010) [62] using DTI and VBM techniques, identified
a relationship between hippocampal deafferentation and regional brain atrophy in TLE
patients; this hippocampal fibre disconnection may be partially responsible for grey matter
atrophy in temporal, basal nuclei, and cerebellar areas. The presence of HS, however,
does not necessarily imply cerebellar atrophy. In other words, cerebellar volume loss
was identified, even in the absence of HS [64,65] and prolonged seizure freedom did not
prevent cerebellar atrophy [69]. These findings are supportive of the growing evidence
that the distribution of atrophy within the brain of TLE patients, preferentially affects
brain structures that are anatomically and functionally connected to the hippocampus and
cerebellum [62]. However, the high prevalence of pharmaco-resistant TLE patients with
cerebellar degeneration may reflect the lack of routine neuroimaging in drug-responsive
patients, patients with generalised epilepsy, and those with no clinical deficits [82].
4.2. Pharmaco-Resistance and Cerebellar Degeneration
Epilepsy treatment has evolved significantly, from the traditional use of bromides,
to the modern era in which we now utilise various treatment modalities. These include
medications, implantable devices, non-pharmacological therapies, and surgery [83]. AEDs
remain the mainstay treatment options for epilepsy, with approximately 50% of patients
becoming seizure free with monotherapy [84]. However, only 11% of patients who fail to
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achieve seizure freedom with monotherapy, due to inefficacy, experience a reduction with
a second treatment option [85]. These findings suggest that the probability of treatment
response reduces with each treatment failure [86,87]. Although, the terms “refractory”,
“intractable”, and “pharmaco-resistant” epilepsy are used interchangeably. The ILAE
defines “drug-resistant epilepsy” as a failure to achieve and maintain seizure freedom
despite trialling two AEDs that are well tolerated, in terms of side effects, whether as a
monotherapy or polytherapy [88].
Approximately 30 to 40% of patients with epilepsy fail to achieve adequate control of
seizures, despite the use of multiple AEDs and different treatment therapies [89]. Our re-
view identified an exceedingly high prevalence of drug-resistant patients that demonstrated
cerebellar degeneration (87.2%). This is consistent with the general consensus that drug-
resistant epilepsy has more profound brain damage than drug-responsive epilepsy [77,90].
Factors that induce cerebellar degeneration in pharmaco-resistant patients remain to be
determined, whether this is related to seizure mediated cell loss or from direct effects of
status epilepticus or from the use of multiple AEDs at high serum concentrations.
Patients responsive to AED treatment were also observed to have cerebellar degen-
eration, indicating that multiple factors may contribute to the development of cerebellar
degeneration in epilepsy [61]. However Bilevicius et al., (2010) [61] found that cerebellar
degeneration in patients with drug-resistant and relapsing-remitting seizures was more
profound and widespread than drug-responsive epilepsy. Despite this, there is a paucity
of studies evaluating the influence of seizure control on cerebellar degeneration. There
may be bias in performing neuroimaging only in patients with pharmaco-resistant epilepsy.
Studies evaluating cerebellar degeneration should include both patients with uncontrolled
epilepsy as well as stable epilepsy.
4.3. Phenytoin and Cerebellar Degeneration
The correct choice of an AED is crucial to therapeutic success. Our review identi-
fied an increased number of patients using phenytoin. Since its introduction to epilepsy
treatment in 1938, phenytoin had become the most extensively prescribed and studied
anticonvulsant [91]. It acts by blocking voltage-dependent sodium channels, suppressing
the propagation of discharges from seizures. However, due to the narrow therapeutic
index of phenytoin; its risks of acute over-dosage and the toxicity effects of its chronic
use [92], phenytoin is now gradually becoming less popular. Long-term use of phenytoin
has already been associated with significant risk of cerebellar degeneration and ataxia,
which can persist long after discontinuation [7].
The chronic effects of phenytoin are often difficult to discriminate from that of the
seizures [43]; as the analyses are complicated by the fact that patients with severe epilepsy
are also on higher doses of medication [50]. Despite this, our findings lend confidence
to the notion that chronic phenytoin use, whether in the therapeutic range or not, is an
important factor of cerebellar degeneration. As we are now in an era whereby there is
a variety of viable AED options, it would be interesting to compare phenytoin-exposed
patients with those that have not been exposed [20]. Phenytoin use in epilepsy may be
much higher than any other AED; thus, the connection with cerebellar degeneration may
simply be because it is used frequently. Proportionally more patients on phenytoin develop
ataxia than patients on other AED. Further studies should focus in comparing phenytoin
as monotherapy and/or combination therapy with other AED and treatment duration in
determining its link with cerebellar degeneration.
4.4. Clinical Characteristics of Cerebellar Degeneration
Previous research has demonstrated a weak relationship between the clinical manifes-
tations of cerebellar dysfunction and neuroimaging characteristics of cerebellar atrophy [93].
In our review, cerebellar degeneration by assessment of cerebellar atrophy was evidenced
in 86.7% of patients with epilepsy. Whether this was related to the toxic effects of AEDs
or drug-resistant epilepsy or the use of polytherapy as a treatment mechanism; or the
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combination of all three, remains unclear. Although, studies evaluated on their own merits
did not find a link between cerebellar atrophy in neuroimaging and the clinical evidence of
ataxia, Shanmugarajah et al., (2018) [41] identified significantly smaller cerebellar volumes
in patients with phenytoin related ataxia, compared with patients taking phenytoin with-
out ataxia. These findings suggest a possible threshold by which cerebellar atrophy may
manifest clinically with cerebellar signs.
Although studies have postulated that ataxia is a direct result of cerebellar atro-
phy [55,57], others have found no association between the presence or absence of cerebellar
atrophy on the clinical manifestation of ataxia [33,37], or of the severity of symptoms [35].
Ataxia, in all available studies, was associated with the cerebellar atrophy. Reports
on peripheral neuropathy were limited, therefore no conclusions could be derived in this
regard. Although we aimed to examine neuropathological studies in our review, these
were limited in our search.
5. Limitations
Several confounding variables can be drawn from the population demographics. Some
studies included patients with additional features such as headache and migraine [20,32,42,49],
history of alcoholism [52,72], and intellectual disabilities [29,36,66]. Some studies were
retrospective. Studies that employ this method are subject to various risks of validity;
because they rely on the accuracy of written medical records, controlling for bias and
confounding variables is challenging, and establishing cause and effect proves difficult [94].
In addition, the retrospective feature of these studies may introduce selection bias [95],
as some studies recruited from specialised centres or hospital clinics, with a predilection
towards chronic, severe, and often drug-resistant epilepsy [50].
Some studies used a cross-sectional design, which cannot infer causality. This is
especially important where the age of onset and duration of epilepsy are concerned [63].
As such, inferences on disease progression over time, in particular, the effects of chronic
epilepsy on changes in brain morphology, are limited [28]. This is because subtle changes in
brain structure are difficult to detect over the large inter-patient variability [27]. We aimed
to determine the clinical characteristics of cerebellar dysfunction in patients with epilepsy.
However, the presence of it does not necessarily indicate cerebellar degeneration as similar
signs can be seen in AED intoxication. Future studies defining clinical characteristics
should exclude intoxication as a cause by performing serum AED levels simultaneously.
There were significant variations across neuroimaging studies [57]. Firstly, due to
a lack of well-defined criteria, diagnosis of atrophy is often based on manual tracing of
the cerebellum and subjective interpretations [50]. Specht et al., (1997) [21] identified that
MRI ratings of cerebellar atrophy differed by 37% between two independent neurologists,
thus introducing inter-rater bias [37]. Secondly, emerging literature suggests that volumes
obtained from volumetric MRIs vary according to manufacturer [82], scanner type, field
strength, and slice thickness [96]. Taking these points into consideration, future studies
should consider using 1.5 Tesla magnet and thinner slices to obtain an accurate and reliable
measure of the cerebellum [96].
Following the work of the ILAE, the definitions and criteria for epilepsy diagnosis
are evolving [97]. It is thus not possible to determine whether we have reported accurate
prevalence rates for different epilepsies. Due to the broad publication dates of included
studies, spanning just over a four-decade period and variation, we cannot be certain how
stringently the ILAE guidelines were followed or if they were followed at all. The primary
concern of defining epilepsy is not straight forward. Where definitions were provided,
these consisted of standard definitions established by the ILAE criteria, which would have
been relevant for that time period. Whereas, other definitions specified variable diagnostic
criteria, in relation to clinical evaluation, EEG recordings and neurological examinations,
such as number of seizures and treatment with AED medications.
The prevalence of phenytoin use overall compared to other AEDs may have influenced
the results. Phenytoin was consistently the highest used AED in all sections of our review.
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The articles used in this review were retrieved via a search in a single electronic
database, PubMed. Bramer et al., (2017) [98] recommended systematic reviews should
utilise a combination of MEDLINE, Embase, Web of Science Core Collection and Google
Scholar databases, in order to achieve >95% literature recall.
6. Future Studies
As well as considering the limitations in our review, future studies would benefit
from a more stringent exclusion criteria, excluding patients with alcohol misuse; those
cognitively impaired and patients with epilepsy with structural lesions. Furthermore,
research should focus on conducting multicohort longitudinal studies. The study should
be of a sufficient sample size and with adequate power, in order to identify variations of
clinical significance, and unequivocally differentiate disease progression from natural age-
related atrophy. Longitudinal studies will enable detection of physical changes of cerebellar
degeneration between patients with epilepsy and healthy controls [99]. Studies should
also appreciate the heterogeneous nature of epilepsy, the various different AEDs including
newer agents, and consider investigating cerebellar degeneration in relation to patients
with seizure freedom to identify the extent of brain damage from seizures themselves.
7. Conclusions
In summary, cerebellar degeneration is prevalent in patients with epilepsy. This
review identified a trio of predictors of cerebellar degeneration. Patients with temporal
lobe epilepsy, patients with drug-resistant epilepsy and those treated with chronic use of
phenytoin were most susceptible to cerebellar degeneration. Whether cerebellar atrophy is
a predisposing factor for cerebellar ataxia in patients with epilepsy is inconclusive, due to
the lack of clinical symptom reporting. Further prospective studies are required to confirm
if the predictors identified in this review are indeed linked to cerebellar degeneration and
to establish the pathogenic mechanisms that result in cerebellar insult.
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